Which blood thinner combo best prevents a second stroke?
NCT ID NCT06591377
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study tests whether adding ticagrelor or cilostazol to aspirin is better at preventing new strokes in people who recently had a minor stroke or TIA. 900 adults aged 18-75 will take one of the two combinations for 90 days. Researchers will track how many have another stroke and any bleeding side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
El-sahel teaching hospital
RECRUITINGCairo, 22514, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kafr Elsheikh University Hospital
RECRUITINGKafr ash Shaykh, 33511, Egypt
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ticagrelor and cilostazol (antiplatelet drugs)
What this could lead to
If successful, this could identify a better drug combination to prevent a second stroke after a minor stroke or TIA.
What could go wrong
This is an early-phase trial with 900 participants, so results may not apply to everyone. Both drugs increase bleeding risk, which could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.